Does the media refer more to FTH or CHRS?

In the previous week, Sensei Biotherapeutics and Sensei Biotherapeutics both had 2 articles in the media. Coherus Oncology's average media sentiment score of 1.47 beat Sensei Biotherapeutics' score of 0.96 indicating that Coherus Oncology is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sensei Biotherapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Coherus Oncology 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor CHRS or RIGL?

In the previous week, Rigel Pharmaceuticals had 4 more articles in the media than Coherus Oncology. MarketBeat recorded 6 mentions for Rigel Pharmaceuticals and 2 mentions for Coherus Oncology. Rigel Pharmaceuticals' average media sentiment score of 1.54 beat Coherus Oncology's score of 1.47 indicating that Rigel Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Coherus Oncology 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Rigel Pharmaceuticals 5 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media refer more to PHAR or CHRS?

In the previous week, Pharming Group had 2 more articles in the media than Coherus Oncology. MarketBeat recorded 4 mentions for Pharming Group and 2 mentions for Coherus Oncology. Coherus Oncology's average media sentiment score of 1.47 beat Pharming Group's score of 1.00 indicating that Coherus Oncology is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pharming Group 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Coherus Oncology 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor CHRS or SLN?

In the previous week, Coherus Oncology and Coherus Oncology both had 2 articles in the media. Silence Therapeutics' average media sentiment score of 1.61 beat Coherus Oncology's score of 1.47 indicating that Silence Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Coherus Oncology 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Silence Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media prefer CHRS or NGNE?

In the previous week, Neurogene had 2 more articles in the media than Coherus Oncology. MarketBeat recorded 4 mentions for Neurogene and 2 mentions for Coherus Oncology. Neurogene's average media sentiment score of 1.76 beat Coherus Oncology's score of 1.47 indicating that Neurogene is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Coherus Oncology 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Neurogene 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Coherus Oncology (CHRS) Competitors

$1.41 -0.05 (-3.42%)

As of 08/28/2026 04:00 PM Eastern

Compare

CHRS vs. FTH, RIGL, PHAR, SLN, and NGNE

Should you buy Coherus Oncology stock or one of its competitors? Coherus Oncology's main competitors and comparable companies include Sensei Biotherapeutics (FTH), Rigel Pharmaceuticals (RIGL), Pharming Group (PHAR), Silence Therapeutics (SLN), and Neurogene (NGNE). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Coherus Oncology compare to Sensei Biotherapeutics?

Sensei Biotherapeutics (NASDAQ:FTH) and Coherus Oncology (NASDAQ:CHRS) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, valuation, profitability, earnings, media sentiment, institutional ownership and risk.

10.5% of Sensei Biotherapeutics shares are owned by institutional investors. Comparatively, 72.8% of Coherus Oncology shares are owned by institutional investors. 7.0% of Sensei Biotherapeutics shares are owned by company insiders. Comparatively, 7.2% of Coherus Oncology shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Sensei Biotherapeutics presently has a consensus price target of $55.00, indicating a potential upside of 62.53%. Coherus Oncology has a consensus price target of $8.67, indicating a potential upside of 514.66%. Given Coherus Oncology's higher possible upside, analysts plainly believe Coherus Oncology is more favorable than Sensei Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sensei Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.85
Coherus Oncology	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75

Coherus Oncology has higher revenue and earnings than Sensei Biotherapeutics. Coherus Oncology is trading at a lower price-to-earnings ratio than Sensei Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sensei Biotherapeutics	N/A	N/A	-$21.08M	-$141.65	N/A
Coherus Oncology	$42.17M	5.17	$168.02M	-$1.03	N/A

Sensei Biotherapeutics has a beta of -0.25, suggesting that its share price is 125% less volatile than the broader market. Comparatively, Coherus Oncology has a beta of 0.98, suggesting that its share price is 2% less volatile than the broader market.

Sensei Biotherapeutics has a net margin of 0.00% compared to Coherus Oncology's net margin of -259.41%. Coherus Oncology's return on equity of -222.75% beat Sensei Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sensei Biotherapeutics	N/A	-1,012.17%	-175.69%
Coherus Oncology	-259.41%	-222.75%	-52.11%

In the previous week, Sensei Biotherapeutics and Sensei Biotherapeutics both had 2 articles in the media. Coherus Oncology's average media sentiment score of 1.47 beat Sensei Biotherapeutics' score of 0.96 indicating that Coherus Oncology is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sensei Biotherapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Coherus Oncology	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Coherus Oncology beats Sensei Biotherapeutics on 10 of the 15 factors compared between the two stocks.

How does Coherus Oncology compare to Rigel Pharmaceuticals?

Coherus Oncology (NASDAQ:CHRS) and Rigel Pharmaceuticals (NASDAQ:RIGL) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, earnings, profitability, dividends, risk, institutional ownership, media sentiment and analyst recommendations.

Rigel Pharmaceuticals has a net margin of 116.30% compared to Coherus Oncology's net margin of -259.41%. Rigel Pharmaceuticals' return on equity of 22.95% beat Coherus Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Coherus Oncology	-259.41%	-222.75%	-52.11%
Rigel Pharmaceuticals	116.30%	22.95%	17.19%

72.8% of Coherus Oncology shares are owned by institutional investors. Comparatively, 66.2% of Rigel Pharmaceuticals shares are owned by institutional investors. 7.2% of Coherus Oncology shares are owned by company insiders. Comparatively, 10.5% of Rigel Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Coherus Oncology presently has a consensus price target of $8.67, indicating a potential upside of 514.66%. Rigel Pharmaceuticals has a consensus price target of $59.00, indicating a potential upside of 26.94%. Given Coherus Oncology's stronger consensus rating and higher probable upside, analysts clearly believe Coherus Oncology is more favorable than Rigel Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Coherus Oncology	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75
Rigel Pharmaceuticals	0 Sell rating(s)	4 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.43

In the previous week, Rigel Pharmaceuticals had 4 more articles in the media than Coherus Oncology. MarketBeat recorded 6 mentions for Rigel Pharmaceuticals and 2 mentions for Coherus Oncology. Rigel Pharmaceuticals' average media sentiment score of 1.54 beat Coherus Oncology's score of 1.47 indicating that Rigel Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Coherus Oncology	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Rigel Pharmaceuticals	5 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Rigel Pharmaceuticals has higher revenue and earnings than Coherus Oncology. Coherus Oncology is trading at a lower price-to-earnings ratio than Rigel Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Coherus Oncology	$42.17M	5.17	$168.02M	-$1.03	N/A
Rigel Pharmaceuticals	$276.79M	3.11	$367.02M	$16.32	2.85

Coherus Oncology has a beta of 0.98, indicating that its share price is 2% less volatile than the broader market. Comparatively, Rigel Pharmaceuticals has a beta of 1.16, indicating that its share price is 16% more volatile than the broader market.

Summary

Rigel Pharmaceuticals beats Coherus Oncology on 11 of the 15 factors compared between the two stocks.

How does Coherus Oncology compare to Pharming Group?

Pharming Group (NASDAQ:PHAR) and Coherus Oncology (NASDAQ:CHRS) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, media sentiment, analyst recommendations, dividends, profitability, valuation, risk and earnings.

0.0% of Pharming Group shares are held by institutional investors. Comparatively, 72.8% of Coherus Oncology shares are held by institutional investors. 2.1% of Pharming Group shares are held by company insiders. Comparatively, 7.2% of Coherus Oncology shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Pharming Group had 2 more articles in the media than Coherus Oncology. MarketBeat recorded 4 mentions for Pharming Group and 2 mentions for Coherus Oncology. Coherus Oncology's average media sentiment score of 1.47 beat Pharming Group's score of 1.00 indicating that Coherus Oncology is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pharming Group	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Coherus Oncology	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Coherus Oncology has lower revenue, but higher earnings than Pharming Group. Coherus Oncology is trading at a lower price-to-earnings ratio than Pharming Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pharming Group	$376.13M	2.20	$2.85M	$0.12	97.50
Coherus Oncology	$42.17M	5.17	$168.02M	-$1.03	N/A

Pharming Group has a net margin of 2.51% compared to Coherus Oncology's net margin of -259.41%. Pharming Group's return on equity of 3.40% beat Coherus Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pharming Group	2.51%	3.40%	1.90%
Coherus Oncology	-259.41%	-222.75%	-52.11%

Pharming Group currently has a consensus price target of $38.67, suggesting a potential upside of 230.48%. Coherus Oncology has a consensus price target of $8.67, suggesting a potential upside of 514.66%. Given Coherus Oncology's stronger consensus rating and higher possible upside, analysts clearly believe Coherus Oncology is more favorable than Pharming Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pharming Group	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20
Coherus Oncology	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75

Pharming Group has a beta of -0.01, meaning that its share price is 101% less volatile than the broader market. Comparatively, Coherus Oncology has a beta of 0.98, meaning that its share price is 2% less volatile than the broader market.

Summary

Coherus Oncology beats Pharming Group on 8 of the 15 factors compared between the two stocks.

How does Coherus Oncology compare to Silence Therapeutics?

Coherus Oncology (NASDAQ:CHRS) and Silence Therapeutics (NASDAQ:SLN) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, media sentiment, profitability, institutional ownership, valuation and earnings.

72.8% of Coherus Oncology shares are owned by institutional investors. Comparatively, 98.7% of Silence Therapeutics shares are owned by institutional investors. 7.2% of Coherus Oncology shares are owned by company insiders. Comparatively, 3.0% of Silence Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Coherus Oncology has a net margin of -259.41% compared to Silence Therapeutics' net margin of -8,943.86%. Silence Therapeutics' return on equity of -106.94% beat Coherus Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Coherus Oncology	-259.41%	-222.75%	-52.11%
Silence Therapeutics	-8,943.86%	-106.94%	-47.99%

Coherus Oncology has higher revenue and earnings than Silence Therapeutics. Silence Therapeutics is trading at a lower price-to-earnings ratio than Coherus Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Coherus Oncology	$42.17M	5.17	$168.02M	-$1.03	N/A
Silence Therapeutics	$615K	1,313.83	-$88.61M	-$1.28	N/A

Coherus Oncology has a beta of 0.98, suggesting that its share price is 2% less volatile than the broader market. Comparatively, Silence Therapeutics has a beta of 1.39, suggesting that its share price is 39% more volatile than the broader market.

In the previous week, Coherus Oncology and Coherus Oncology both had 2 articles in the media. Silence Therapeutics' average media sentiment score of 1.61 beat Coherus Oncology's score of 1.47 indicating that Silence Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Coherus Oncology	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Silence Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Coherus Oncology currently has a consensus target price of $8.67, suggesting a potential upside of 514.66%. Silence Therapeutics has a consensus target price of $53.50, suggesting a potential upside of 298.66%. Given Coherus Oncology's higher possible upside, equities analysts clearly believe Coherus Oncology is more favorable than Silence Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Coherus Oncology	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75
Silence Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83

Summary

Silence Therapeutics beats Coherus Oncology on 9 of the 16 factors compared between the two stocks.

How does Coherus Oncology compare to Neurogene?

Coherus Oncology (NASDAQ:CHRS) and Neurogene (NASDAQ:NGNE) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, media sentiment, earnings, analyst recommendations, valuation, risk, dividends and institutional ownership.

In the previous week, Neurogene had 2 more articles in the media than Coherus Oncology. MarketBeat recorded 4 mentions for Neurogene and 2 mentions for Coherus Oncology. Neurogene's average media sentiment score of 1.76 beat Coherus Oncology's score of 1.47 indicating that Neurogene is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Coherus Oncology	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Neurogene	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Coherus Oncology has higher revenue and earnings than Neurogene. Neurogene is trading at a lower price-to-earnings ratio than Coherus Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Coherus Oncology	$42.17M	5.17	$168.02M	-$1.03	N/A
Neurogene	$930K	787.06	-$90.35M	-$5.03	N/A

72.8% of Coherus Oncology shares are owned by institutional investors. Comparatively, 52.4% of Neurogene shares are owned by institutional investors. 7.2% of Coherus Oncology shares are owned by company insiders. Comparatively, 11.7% of Neurogene shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Coherus Oncology currently has a consensus target price of $8.67, indicating a potential upside of 514.66%. Neurogene has a consensus target price of $83.67, indicating a potential upside of 128.72%. Given Coherus Oncology's higher possible upside, equities analysts clearly believe Coherus Oncology is more favorable than Neurogene.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Coherus Oncology	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75
Neurogene	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83

Neurogene has a net margin of 0.00% compared to Coherus Oncology's net margin of -259.41%. Neurogene's return on equity of -45.10% beat Coherus Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Coherus Oncology	-259.41%	-222.75%	-52.11%
Neurogene	N/A	-45.10%	-41.00%

Coherus Oncology has a beta of 0.98, meaning that its stock price is 2% less volatile than the broader market. Comparatively, Neurogene has a beta of 1.7, meaning that its stock price is 70% more volatile than the broader market.

Summary

Neurogene beats Coherus Oncology on 11 of the 17 factors compared between the two stocks.

Get Coherus Oncology News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CHRS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CHRS vs. The Competition

Export

Metric	Coherus Oncology	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$217.85M	$3.93B	$7.20B	$12.90B
Dividend Yield	N/A	3.61%	2.54%	11.28%
P/E Ratio	-1.37	11.62	273.16	25.45
Price / Sales	5.17	1,295.47	604.43	75.83
Price / Cash	N/A	106.39	76.74	53.00
Price / Book	3.62	16.53	12.98	6.14
Net Income	$168.02M	-$22.80M	$3.48B	$348.86M
7 Day Performance	-0.70%	-0.31%	0.13%	-0.80%
1 Month Performance	-4.08%	9.80%	7.08%	4.13%
1 Year Performance	21.55%	55.66%	24.67%	15.17%

Coherus Oncology Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CHRS Coherus Oncology	2.3066 of 5 stars	$1.41 -3.4%	$8.67 +514.7%	+21.6%	$217.85M	$42.17M	N/A	330	Gap Up
FTH Sensei Biotherapeutics	4.2505 of 5 stars	$32.93 -5.1%	$55.00 +67.0%	N/A	$850.89M	N/A	N/A	40
RIGL Rigel Pharmaceuticals	4.5427 of 5 stars	$45.41 +0.7%	$59.00 +29.9%	+19.6%	$840.09M	$294.28M	2.78	160	Positive News Analyst Downgrade
PHAR Pharming Group	3.7341 of 5 stars	$11.83 +3.2%	$38.67 +226.8%	-21.2%	$837.38M	$366.48M	98.59	280	Short Interest Increase
SLN Silence Therapeutics	3.0761 of 5 stars	$13.95 +5.0%	$53.50 +283.5%	+179.0%	$835.35M	$560K	N/A	100	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CHRS) was last updated on 8/30/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Coherus Oncology (CHRS) Competitors

CHRS vs. FTH, RIGL, PHAR, SLN, and NGNE

How does Coherus Oncology compare to Sensei Biotherapeutics?

Summary

How does Coherus Oncology compare to Rigel Pharmaceuticals?

Summary

How does Coherus Oncology compare to Pharming Group?

Summary

How does Coherus Oncology compare to Silence Therapeutics?

Summary

How does Coherus Oncology compare to Neurogene?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CHRS vs. The Competition

Coherus Oncology Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Coherus Oncology (CHRS) Competitors

CHRS vs. FTH, RIGL, PHAR, SLN, and NGNE

How does Coherus Oncology compare to Sensei Biotherapeutics?

Do institutionals & insiders believe in FTH or CHRS?

Do analysts rate FTH or CHRS?

Which has preferable valuation and earnings, FTH or CHRS?

Which has more volatility & risk, FTH or CHRS?

Is FTH or CHRS more profitable?

Does the media refer more to FTH or CHRS?

Summary

How does Coherus Oncology compare to Rigel Pharmaceuticals?

Is CHRS or RIGL more profitable?

Do institutionals and insiders have more ownership in CHRS or RIGL?

Do analysts rate CHRS or RIGL?

Does the media favor CHRS or RIGL?

Which has stronger earnings and valuation, CHRS or RIGL?

Which has more volatility and risk, CHRS or RIGL?

Summary

How does Coherus Oncology compare to Pharming Group?

Do institutionals & insiders believe in PHAR or CHRS?

Does the media refer more to PHAR or CHRS?

Which has preferable earnings & valuation, PHAR or CHRS?

Is PHAR or CHRS more profitable?

Do analysts prefer PHAR or CHRS?

Which has more volatility and risk, PHAR or CHRS?

Summary

How does Coherus Oncology compare to Silence Therapeutics?

Do institutionals and insiders hold more shares of CHRS or SLN?

Is CHRS or SLN more profitable?

Which has higher earnings & valuation, CHRS or SLN?

Which has more risk & volatility, CHRS or SLN?

Does the media favor CHRS or SLN?

Do analysts prefer CHRS or SLN?

Summary

How does Coherus Oncology compare to Neurogene?

Does the media prefer CHRS or NGNE?

Which has preferable earnings and valuation, CHRS or NGNE?

Do institutionals & insiders have more ownership in CHRS or NGNE?

Do analysts recommend CHRS or NGNE?

Is CHRS or NGNE more profitable?

Which has more volatility & risk, CHRS or NGNE?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CHRS vs. The Competition

Coherus Oncology Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools